11 diciembre 2012

PM01183 ( Lurbinectedin PharmaMar ) . Cancer Research UK . A trial looking Phase II for pancreatic cancer . This trial is no longer recruiting patients. We hope to add results when they are available .

Recruitment Phase II :


Start 01/01/2012
End 04/12/2012


Location of trial :

 London , Glasgow and Leeds .










***********************



Pancreatic cancer that has spread to other parts of the body is sometimes called advanced pancreatic cancer. Doctors usually treat this with chemotherapy including the drug gemcitabine. Sadly this doesn’t always work very well so doctors want to find new drugs to help people with advanced pancreatic cancer.
PM01183 is a new drug that affects how cancer cells divide and grow. Researchers want to find out if it can help people with advanced pancreatic cancer.

The aim of this trial is to find out

If PM01183 can help people with advanced pancreatic cancer that has come back or did not go away with chemotherapy

About the side effects .

Chief Investigator : Dr David Cunningham

Supported by : Pharma Mar